Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study

Abstract

Background Multiple guidelines for pancreatic ductal adenocarcinoma (PDAC) suggest that all stages of patients need to receive postoperative adjuvant chemotherapy. S-1 is a recently emerged oral antitumour agent recommended by the guidelines. However, which population would benefit from S-1 needs to be determined, and predictors of chemotherapy response are needed for personalized precision medicine. This pilot study aimed to initially identify whether whole-tumour evaluation with MRI and radiomics features could be used for predicting the efficacy of S-1 and to find potential predictors of the efficacy of S-1 as evidence to assist personalized precision treatment. Methods Forty-six patients with PDAC (31 in the primary cohort and 15 in the validation cohort) who underwent curative resection and subsequently adjuvant chemotherapy with S-1 were included. Pre-operative abdominal contrast-enhanced MRI was performed, and radiomics features of the whole PDAC were extracted from the primary cohort. After univariable analysis and radiomics features selection, a multivariable Cox regression model for survival analysis was subsequently used to select statistically significant factors associated with postoperative disease-free survival (DFS). Predictive capacities of the factors were tested on the validation cohort by using Kaplan–Meier method. Results Multivariable Cox regression analysis identified the probability of T1WI_NGTDM_Strength and tumour location as independent predictors of the efficacy of S-1 for adjuvant chemotherapy of PDAC (p = 0.005 and 0.013) in the primary cohort, with hazard ratios (HRs) of 0.289 and 0.293, respectively. Further survival analysis showed that patients in the low-T1WI_NGTDM_Strength group had shorter DFS (median = 5.1 m) than those in the high-T1WI_NGTDM_Strength group (median = 13.0 m) (p = 0.006), and patients with PDAC on the pancreatic head exhibited shorter DFS (median = 7.0 m) than patients with tumours in other locations (median = 20.0 m) (p = 0.016). In the validation cohort, the difference in DFS between patients with low-T1WI_NGTDM_Strength and high-T1WI_NGTDM_Strength and the difference between patients with PDAC on the pancreatic head and that in other locations were approved, with marginally significant (p = 0.073 and 0.050), respectively. Conclusions Whole-tumour radiomics feature of T1WI_NGTDM_Strength and tumour location were potential predictors of the efficacy of S-1 and for the precision selection of S-1 as adjuvant chemotherapy regimen for PDAC.

A more objective PD diagnostic model: integrating texture feature markers of cerebellar gray matter and white matter through machine learning

“…A run length refers to a sequence of consecutive pixels in a specific direction that had the same gray level. NGTDM was a method for characterizing image texture, taking into account the differences in gray level values between a pixel and the pixels in its neighborhood (Liang et al, 2021 ).…”

Machine Learning of Histopathological Images Predicts Recurrences of Resected Pancreatic Ductal Adenocarcinoma With Adjuvant Treatment

“…S-1 treatment has been shown to be slightly superior to gemcitabine treatment in adjuvant use for patients with resected pancreatic cancer, which helps explain its wide use for pancreatic cancer patients in many countries 11 . The efficacy of S-1 therapy is reported to be associated with the location of pancreatic cancer, features on MRI, 23 and the expression of human equilibrative nucleoside transporter 1 24 . However, the association between S-1 resistance and histopathological features remains unclear.…”

Artificial Intelligence in the Diagnosis and Treatment of Pancreatic Cystic Lesions and Adenocarcinoma

“…Proof-of-concept studies have provided promising evidence for AI in predicting responses to various treatments. Liang et al (2021) used a multivariate Cox regression model to identify radiomics features from pre-operative MRIs that could predict individual response to a new oral therapy (S-1) as an adjuvant chemotherapy and postoperative disease-free survival [95]. Tumor location and another imaging feature were significant predictors of S-1 efficacy, with mass in the pancreatic head being associated with lower treatment efficacy and survival.…”